// App-Quantinova.ai

3472 : Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Report of All 153 Patients Treated in the UK

Researchers

Presenter

  • Richard J Kelly

Principal Investigators

  • Austin G Kulasekararaj

  • Gemma L Brooksbank

  • Tracy Downing

  • Claire McKinley

  • Dena Cohen

  • Walter M Gregory

  • Judith C. W. Marsh

  • Ghulam J. Mufti

  • Peter Hillmen

  • Shreyans A Gandhi

  • Lindsay D Mitchell

  • Modupe Elebute

  • Stephen John Richards

  • Matthew Cullen

  • Louise M Arnold

  • Joanna Large

  • Alexandra Wood

Medical Centers

  • Department of Haematological Medicine, King's College London, London, United Kingdom

  • Clinical Trials Research Unit, University of Leeds, Leeds, United Kingdom

  • Department of Haematology, York Hospital, York, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

  • Chronic kidney disease

  • Pulmonary arterial hypertension

  • Renal insufficiency

  • Aplastic anemia

  • Renal disease

  • Hypertension

  • Sepsis

  • Venous thrombosis

  • Dyspnea

  • Anemia

Biomarkers

  • Lactate dehydrogenase

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Eculizumab

  • Penicillin

  • Benzylpenicillin

  • Warfarin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved